The present invention relates to a pharmaceutical combination which comprises (a) an mTOR catalytic inhibitor, such as a catalytic phosphatidylinositol- 3-kinase (PI3K) and mTOR inhibitor compound which is an imidazoquinoline derivative and (b) at least one allosteric mTOR inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of an mammalian target of rapamycin (mTOR) kinase dependent proliferative diseases； and the uses of such a combination in the treatment of mTOR kinase dependent proliferative diseases； a pharmaceutical composition comprising such a combination； the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease； a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use； and to a method of treatment of a warm-blooded animal, especially a human.本發明係關於醫藥組合，其包含(a) mTOR催化抑制劑，例如催化磷脂醯肌醇-3-激酶(PI3K)及mTOR抑制劑化合物，其為咪唑并喹啉衍生物，及(b)至少一種異位(allo-steric) mTOR抑制劑化合物，及視情況至少一種醫藥上可接受之載劑，同時、各別或相繼使用，特別用於治療哺乳動物雷帕黴素(rapamycin)靶(mTOR)激酶依賴性增殖性疾病；及此組合在治療mTOR激酶依賴性增殖性疾病之用途；包含此組合之醫藥組合物；此組合用於製備用於治療增殖性疾病之藥劑之用途；包含此組合作為同時、各別或相繼使用之組合製劑之商業包裝或產品；及治療溫血動物、尤其人類之方法。
